Robert John Motzer
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
- Cancer Research top 0.01%
- Cancer Genomics and Diagnostics
Papers in
-
- Renal cell carcinoma treatment 449
- Cancer Research 109
- Cancer Genomics and Diagnostics 98
- Co-authors
- George J. Bosl (125 shared papers)PAUL A. J. RUSSO (80 shared papers)Robert A. Figlin (36 shared papers)Jennifer Bacik (31 shared papers)Thomas E. Hutson (47 shared papers)Madhu Mazumdar (29 shared papers)Marc Dror Michaelson (31 shared papers)Ronald M. Bukowski (22 shared papers)
- Journals
- Journal of Clinical Oncology (93 papers)Annals of Oncology (64 papers)The Journal of Urology (43 papers)Cancer (35 papers)Clinical Cancer Research (27 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Robert John Motzer
703 papers receiving 93.0k citations
Robert John Motzer's Hit Papers
Peers
Comparison fields: 5 of 159
- Pulmonary and Respiratory Medicine 53.9k
- Cancer Research 18.8k
- Oncology 26.9k
- Molecular Biology 30.4k
- Surgery 13.9k
Countries citing papers authored by Robert John Motzer
This map shows the geographic impact of Robert John Motzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert John Motzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert John Motzer more than expected).
Fields of papers citing papers by Robert John Motzer
This network shows the impact of papers produced by Robert John Motzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert John Motzer. The network helps show where Robert John Motzer may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert John Motzer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 717 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4815 |
| 2 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4810 |
| 3 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 4 | Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 3042 |
| 5 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types Hit paper breakdown → | 2019 | 3019 |
| 6 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2538 |
| 7 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 1971 |
| 8 | Renal-Cell Carcinoma Hit paper breakdown → | 1996 | 1875 |
| 9 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1843 |
| 10 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2013 | 1579 |
| 11 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Hit paper breakdown → | 2011 | 1544 |
| 12 | Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma Hit paper breakdown → | 1999 | 1474 |
| 13 | Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2005 | 1379 |
| 14 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 15 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 16 | Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma Hit paper breakdown → | 2002 | 1285 |
| 17 | Sunitinib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 1025 |
| 18 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Hit paper breakdown → | 2018 | 1011 |
| 19 | Systemic Therapy for Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2017 | 1010 |
| 20 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 1004 |
About Robert John Motzer
Robert John Motzer is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Surgery, Oncology and Molecular Biology, having authored 717 papers that have together received 95.6k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (449 papers), Testicular diseases and treatments (147 papers), Renal and related cancers (117 papers), Cancer Genomics and Diagnostics (98 papers), Cancer Immunotherapy and Biomarkers (58 papers), Pancreatic and Hepatic Oncology Research (32 papers), Neuroblastoma Research and Treatments (29 papers) and Economic and Financial Impacts of Cancer (28 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (53.9k citations), Cancer Research (18.8k citations), Oncology (26.9k citations), Molecular Biology (30.4k citations) and Surgery (13.9k citations). Robert John Motzer has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include George J. Bosl, PAUL A. J. RUSSO, Robert A. Figlin, Jennifer Bacik, Thomas E. Hutson, Madhu Mazumdar, Marc Dror Michaelson, Ronald M. Bukowski, Toni K. Choueiri and Stéphane Marie. Oudard. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Journal of Urology, Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.